Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
FAQ
Apa simbol saham Lysogene?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Muenchen, saham Lysogene diperdagangkan dengan simbol 4W4.MU.
Berapa jumlah karyawan Lysogene?▼
Per 2 November 2026, perusahaan memiliki 22 karyawan.
Lysogene berada di sektor apa?▼
Lysogene beroperasi di sektor Lainnya.
Kapan Lysogene menyelesaikan split saham?▼
Lysogene belum melakukan split saham baru-baru ini.
Di mana kantor pusat Lysogene?▼
Kantor pusat Lysogene berlokasi di Neuilly-sur-Seine, Prancis.